Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis

The Efficacy of Hydroxychloroquine on Behcet's Disease Thrombotic Events Prevention

Patients diagnosed with Behcet's disease will be randomized to administeration of hydroxychloroquine. Assessment will be done for the patients at baseline and every one month in the first three months and then quarterly for one year.

Inclusion Criteria:

• All patients diagnosed with Behcet's disease on any DMARDs

Exclusion Criteria:

• Patients with critical conditions
• Patients with hypersensitivity or adverse drug reactions to hydroxychloroquine.